PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Barclays PLC

Barclays PLC lowered its position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 93.5% during the third quarter, HoldingsChannel reports. The firm owned 30,248 shares of the company’s stock after selling 434,704 shares during the period. Barclays PLC’s holdings in PMV Pharmaceuticals were worth $45,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. ArrowMark Colorado Holdings LLC grew its holdings in shares of PMV Pharmaceuticals by 30.0% in the third quarter. ArrowMark Colorado Holdings LLC now owns 3,647,291 shares of the company’s stock valued at $5,434,000 after purchasing an additional 842,509 shares during the period. Sio Capital Management LLC raised its position in PMV Pharmaceuticals by 18.7% in the third quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company’s stock valued at $4,789,000 after purchasing an additional 505,831 shares during the period. PFM Health Sciences LP grew its holdings in shares of PMV Pharmaceuticals by 57.7% during the 3rd quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company’s stock worth $2,996,000 after purchasing an additional 735,578 shares during the period. BML Capital Management LLC grew its holdings in shares of PMV Pharmaceuticals by 29.0% during the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company’s stock worth $2,516,000 after purchasing an additional 379,375 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of PMV Pharmaceuticals by 36.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company’s stock worth $527,000 after purchasing an additional 93,809 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

PMV Pharmaceuticals Stock Down 1.9 %

PMVP opened at $1.51 on Friday. PMV Pharmaceuticals, Inc. has a 52 week low of $1.40 and a 52 week high of $2.80. The business has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $1.57. The firm has a market cap of $78.14 million, a P/E ratio of -1.51 and a beta of 1.46.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Oppenheimer raised shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Friday, November 8th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $5.50.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.